Bouncing back, MediciNova makes big gains after touting triglyceride data from a tiny study

Shares of MediciNova rocketed up more than 30% this morning after the biotech $MNOV touted the early end of a small Phase IIa NASH study with positive results in cutting the level of triglycerides.

Yuichi Iwaki

According to investigators MN-001 (tipelukast) reduced mean serum triglycerides, a primary endpoint, from an average of 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment, delivering a p value of 0.00006.

They were studying the therapy for NASH and the common second shot at NAFLD — non-alcoholic fatty liver disease. But company execs, coming off a recent setback on its lead drug candidate against methamphetamine dependence, cheered themselves on with a strategy for going after all conditions associated with hypertriglyceridemia.

“Based on the results of this study, along with the triglyceride data we have from prior clinical studies of MN-001 in other indications, we believe that MN-001 has potential to benefit a wide range of patients with hypertriglyceridemia, not limited to those with NASH and NAFLD,” said Yuichi Iwaki, CEO of the La Jolla, CA-based company.

There are a variety of drugs being developed for NASH now, with one of the leading programs at Gilead. Researchers have been using a number of primary and secondary goal posts for these studies, and MediciNova is likely to feel something of a backlash about reading big gains for themselves from a small mid-stage study like this.

According to, the biotech recruited only 40 people for this study, leaving a long, long road ahead in the clinic.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->